Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Review of Virus-Like Particle-Based SARS-CoV-2 Vaccines in Clinical Trial Phases
Mohammad Sharifzadeh, Negar Mottaghi-Dastjerdi, Mohammad Soltany Rezae Raad
Deleted Journal (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Platforms, advances, and technical challenges in virus-like particles-based vaccines
Reeshu Gupta, Kajal Arora, Sourav Singha Roy, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 63
COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic
Aleksandra Anna Zasada, Aniela Darlińska, Aldona Wiatrzyk, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1786-1786
Open Access | Times Cited: 23
Virus‐like particles as powerful vaccination strategy against human viruses
Ikbel Hadj Hassine, Manel Ben M’hadheb-Gharbi, Mohammed A. Almalki, et al.
Reviews in Medical Virology (2023) Vol. 34, Iss. 1
Closed Access | Times Cited: 20
A perspective on SARS-CoV-2 virus-like particles vaccines
Gao Xiaoyang, Yeting Xia, Xiaofang Liu, et al.
International Immunopharmacology (2023) Vol. 115, pp. 109650-109650
Open Access | Times Cited: 18
Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy
Abdellatif Bouazzaoui, Ahmed A. H. Abdellatif
Vaccine X (2024) Vol. 19, pp. 100500-100500
Open Access | Times Cited: 7
mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions
Ryo Okuyama
Vaccines (2023) Vol. 11, Iss. 12, pp. 1737-1737
Open Access | Times Cited: 14
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
Anirudha Chattopadhyay, A. Abdul Kader Jailani, Bikash Mandal
Vaccines (2023) Vol. 11, Iss. 8, pp. 1347-1347
Open Access | Times Cited: 13
Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses
Zichao Huang, Xinyu Zhuang, Liping Liu, et al.
National Science Review (2023) Vol. 11, Iss. 3
Open Access | Times Cited: 11
COVID-19: The vaccine development strategies
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 645-667
Closed Access
Revolutionizing Nanovaccines: A New Era of Immunization
Mohammed A. Saleh, Ahmed El-Moghazy, Adel Helmy Elgohary, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 126-126
Open Access
Simian Immunodeficiency Virus-Based Virus-like Particles Are an Efficient Tool to Induce Persistent Anti-SARS-CoV-2 Spike Neutralizing Antibodies and Specific T Cells in Mice
Alessandra Gallinaro, Chiara Falce, Maria Franca Pirillo, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 216-216
Open Access
Tuning the tropism and infectivity of SARS-CoV-2 virus-like particles for mRNA delivery
Qi Yang, Bruce A. Davidson, Petar Pajic, et al.
Nucleic Acids Research (2025) Vol. 53, Iss. 5
Open Access
Viral protein-based nanoparticles (part 2): Pharmaceutical applications
Rocio Mellid-Carballal, Sara Gutierrez-Gutierrez, Carmen Rivas, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 189, pp. 106558-106558
Open Access | Times Cited: 7
Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?
Manish Dhawan, AbdulRahman A. Saied, Manish Sharma
Health Sciences Review (2023) Vol. 9, pp. 100127-100127
Open Access | Times Cited: 6
Recent Developments in Silver Nanoparticles Utilized for Cancer Treatment and Diagnosis: a Patent Review
Shripad M. Patil, Runjhun Tandon, Nitin Tandon
Pharmaceutical Patent Analyst (2022) Vol. 11, Iss. 6, pp. 175-186
Closed Access | Times Cited: 10
An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines
Doddy Irawan Setyo Utomo, Hamizah Suhaimi, Nor Azila Muhammad Azami, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1506-1506
Open Access | Times Cited: 5
Large-Scale Purification and Characterization of Recombinant Receptor-Binding Domain (RBD) of SARS-CoV-2 Spike Protein Expressed in Yeast
Gaurav Nagar, Siddharth Jain, Meghraj P. Rajurkar, et al.
Vaccines (2023) Vol. 11, Iss. 10, pp. 1602-1602
Open Access | Times Cited: 4
An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines
Dona Susan Mathew, T. Pandya, HC Pandya, et al.
Biomolecules (2023) Vol. 13, Iss. 11, pp. 1565-1565
Open Access | Times Cited: 4
Controlling the Quality of Nanodrugs According to Their New Property—Radiothermal Emission
Gleb V. Petrov, DARIA A. GALKINA, Alena M. Koldina, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 180-180
Open Access | Times Cited: 1
Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of SARS‐CoV‐2 Through Mutant Bacteriophage Qβ—Receptor Binding Domain Conjugate
Zibin Tan, Canchai Yang, Po‐Han Lin, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 20
Closed Access | Times Cited: 1
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
Monrat Chulanetra, Primana Punnakitikashem, Kodchakorn Mahasongkram, et al.
Research Square (Research Square) (2024)
Closed Access
Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines
Nelli S. Khudainazarova, Dmitriy L. Granovskiy, О. А. Кондакова, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11979-11979
Open Access
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
Monrat Chulanetra, Primana Punnakitikashem, Kodchakorn Mahasongkram, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity
Yuhan Li, Xianwen Zhang, Wanbo Tai, et al.
EBioMedicine (2024) Vol. 110, pp. 105437-105437
Closed Access
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial
Beifang Yang, Jing Jin, Xiran He, et al.
Expert Review of Vaccines (2024) Vol. 24, Iss. 1, pp. 81-90
Open Access
Page 1 - Next Page

Scroll to top